These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6211659)

  • 21. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 23. [Severe cardiomyopathy in a woman with intermediate beta-thalassemia. Regression of cardiac failure with desferrioxamine].
    Mancuso L; Iacona MA; Marchi S; Rigano P; Geraci E
    G Ital Cardiol; 1985 Sep; 15(9):916-20. PubMed ID: 4085735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 26. [Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent].
    Baudouy P; Lombrail P; Azancot I; Piekarski A; Martin E; Slama R
    Arch Mal Coeur Vaiss; 1983 Oct; 76(10):1240-6. PubMed ID: 6418103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L; Ferrara M; Galdo Capotorti M
    Pediatria (Napoli); 1978 Mar; 86(1):69-76. PubMed ID: 683795
    [No Abstract]   [Full Text] [Related]  

  • 28. [Arrhythmia in thalassemia major: evaluation of iron chelating therapy by dynamic ECG].
    Cavallaro L; Meo A; Busà G; Coglitore A; Sergi G; Satullo G; Donato A; Calabrò MP; Miceli M
    Minerva Cardioangiol; 1993; 41(7-8):297-301. PubMed ID: 8233011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early impairment of myocardial function in young patients with beta-thalassemia major.
    Magrì D; Sciomer S; Fedele F; Gualdi G; Casciani E; Pugliese P; Losardo A; Ferrazza G; Pasquazzi E; Schifano E; Mussino E; Quaglione R; Piccirillo G
    Eur J Haematol; 2008 Jun; 80(6):515-22. PubMed ID: 18284626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

  • 31. Desferrioxamine: its use in iron chelation in thalassemia.
    Sharma BK; Choudhury P; Dubey AP
    Indian Pediatr; 1990 Mar; 27(3):314-9. PubMed ID: 2190932
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.
    Nienhuis AW; Delea C; Aamodt R; Bartter F; Anderson WF
    Birth Defects Orig Artic Ser; 1976; 12(8):177-85. PubMed ID: 795481
    [No Abstract]   [Full Text] [Related]  

  • 33. [Thalassaemia intermedia. Clinical and laboratory study. Therapeutic suggestions (author's transl)].
    Triadou P; Girot R; Lapoumeroulie C; Pomarede R; Constant S
    Nouv Presse Med; 1982 Jan; 11(4):253-6. PubMed ID: 6173844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The echocardiographic characteristics of cardiac lesions in beta-thalassemia].
    Musaev SK; Babaev AA; Dadasheva TS; Nasonova VA
    Revmatologiia (Mosk); 1990; (2):11-7. PubMed ID: 2218258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lens opacities in thalassemia.
    Bloomfield SE; Markenson AL; Miller DR; Peterson CM
    J Pediatr Ophthalmol Strabismus; 1978; 15(3):154-6. PubMed ID: 739345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

  • 37. [Desferrioxamine-B in the diagnosis of hemosiderotic states and in the therapy of thalassemia. Apropos of 2 cases].
    De Luca G; Faelli U; Petrussa I
    Minerva Pediatr; 1966 Oct; 18(32):1920-5. PubMed ID: 5993655
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical and metabolic research on treatment with desferrioxamine B in various hemosiderotic erythrocyte diseases].
    Cimino R; Quattrin N
    Clin Ter; 1965 Jul; 34(1):3-32. PubMed ID: 5840761
    [No Abstract]   [Full Text] [Related]  

  • 39. Iron excretion in thalassemia after the administration of chelating agents.
    Markum AH; Iskandar W; Keng KL; Odang O
    Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722
    [No Abstract]   [Full Text] [Related]  

  • 40. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.